- Beijing Tongrentang reported net income of 1.02 billion yuan for the first half of 2024.
- This represents a 3.4% increase compared to the previous year’s net income of 986.5 million yuan.
- Revenue for the first half of 2024 remained constant at 9.76 billion yuan, the same as the previous year.
- Analyst ratings reflect strong confidence, with 21 out of 23 maintaining a buy rating.
- There is only one hold rating and one sell rating for Beijing Tongrentang.
A look at Beijing Tongrentang Co A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores for Beijing Tongrentang Co A, the company shows a promising long-term outlook. With strong scores in Growth, Resilience, and Momentum, Beijing Tongrentang Co A is positioned well for future success. The company’s focus on traditional Chinese medicines and medicinal wines, along with its pharmaceutical retail operations, provides a diversified business model that is likely to sustain growth over time.
Additionally, Beijing Tongrentang Co A‘s above-average scores in Dividend and Value indicate a level of stability and attractiveness for investors seeking income and value opportunities in the market. Overall, the company’s strategic positioning in the traditional medicine sector, coupled with its solid financial performance across key factors, bodes well for its future development and potential for long-term success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
